Compare United States Copper Index Fund (CPER) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Enveric Biosciences Inc — how do they compare? United States Copper Index Fund trades at $39.91 (market cap $716.81M), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: United States Copper Index Fund is far larger — about 107.1× Enveric Biosciences Inc's market cap, and United States Copper Index Fund is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Enveric Biosciences Inc for 14 Days on average.
| CPER | ENVB | |
|---|---|---|
Market Cap | $716.81M | $6.69M |
Volume | 388,730 | 41,141 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $10.80 |
52-Week Low | $30.27 | $1.27 |
Typical Hold Time | 48 Days | 14 Days |
Enterprise Value | — | -$1.60M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER trades at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish moving averages but neutral oscillators, with key support at $39. Recent news highlights strong copper demand driven by AI infrastructure, though some articles note price volatility. Financial ratios are unavailable in the provided data.
The outlook for CPER is mixed, balancing positive copper demand trends against near-term price pressure. Investment opportunity lies in exposure to the essential metal for AI and electrification, but risks include commodity price swings and operational challenges in the mining sector. Investors should weigh sector momentum against inherent volatility.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
